Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site

Valuation: Insulet Corporation

Capitalization 22.62B 19.95B 18.6B 16.76B 31.12B 1,927B 34.93B 216B 84.92B 883B 84.82B 83.07B 3,229B P/E ratio 2025 *
80.5x
P/E ratio 2026 * 59.8x
Enterprise value 22.72B 20.05B 18.69B 16.84B 31.27B 1,936B 35.1B 217B 85.32B 887B 85.23B 83.47B 3,244B EV / Sales 2025 *
9.03x
EV / Sales 2026 * 7.53x
Free-Float
99.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.11%
1 week-1.04%
Current month+27.38%
1 month+30.37%
3 months+13.64%
6 months+22.22%
Current year+23.09%
More quotes
1 week 315.91
Extreme 315.91
329.33
1 month 245.66
Extreme 245.655
329.33
Current year 230.05
Extreme 230.05
329.33
1 year 171.61
Extreme 171.61
329.33
3 years 125.82
Extreme 125.82
335.91
5 years 125.82
Extreme 125.82
335.91
10 years 23.94
Extreme 23.94
335.91
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 27/04/2025
Director of Finance/CFO 53 21/04/2024
Chief Tech/Sci/R&D Officer - 11/09/2016
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 60 26/07/2015
Director/Board Member 58 09/08/2017
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.11%-1.04%+88.16%+58.42% 22.62B
-0.15%-2.60%+25.97%+14.14% 228B
-0.28%-6.66%-0.86%-22.62% 103B
+0.77%+0.73%+33.00%+91.45% 56.66B
-0.54%-2.30%-25.60%-33.32% 49.12B
+2.37%+0.81%-3.93%+33.98% 43.12B
-0.38%-1.13%-32.71%+4.36% 33.14B
-0.52%-0.92%+0.60%+31.33% 27.83B
-0.33%-3.41%+7.14%+6.79% 23.87B
-2.48%-4.82%-0.73%-38.72% 21.04B
Average +0.03%-2.13%+9.10%+14.58% 60.93B
Weighted average by Cap. +0.09%-2.61%+12.09%+12.45%
See all sector performances

Financials

2025 *2026 *
Net sales 2.52B 2.22B 2.07B 1.87B 3.46B 214B 3.89B 24.02B 9.45B 98.25B 9.44B 9.25B 359B 2.96B 2.61B 2.43B 2.19B 4.07B 252B 4.57B 28.23B 11.11B 115B 11.09B 10.86B 422B
Net income 291M 257M 239M 216M 401M 24.8B 450M 2.78B 1.09B 11.36B 1.09B 1.07B 41.57B 390M 344M 321M 289M 537M 33.24B 603M 3.72B 1.47B 15.23B 1.46B 1.43B 55.71B
Net Debt 108M 95.27M 88.79M 80M 149M 9.2B 167M 1.03B 405M 4.21B 405M 397M 15.42B -331M -292M -272M -245M -455M -28.16B -510M -3.15B -1.24B -12.9B -1.24B -1.21B -47.19B
More financial data * Estimated data
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.1%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.9%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2024, the group had 2 production sites located in the United States and in China. The United States accounts for 74.7% of net sales.
Employees
3,900
More about the company
Date Price Change Volume
23/05/25 321.36 $ +0.11% 693,225
22/05/25 321.00 $ -1.08% 991,446
21/05/25 324.50 $ -0.91% 653,398
20/05/25 327.47 $ +0.50% 998,439
19/05/25 325.84 $ +0.34% 634,501

Delayed Quote Nasdaq, May 23, 2025 at 09:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
321.36USD
Average target price
328.73USD
Spread / Average Target
+2.29%
Consensus

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
BENEFIT NOW